Jakob R. Izbicki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jakob R. Izbicki has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Klaus Pantel
Institut für Immunologie, Ludwig-Maximilians-Universität, München, Germany
8 shared publications S B Hosch
8 shared publications- Bernward Passlick
Department of Surgery, University of Munich, Munich, Germany
6 shared publications M. Bockhorn
6 shared publications- Wolfram Trudo Knoefel
Department of Surgery (A), Heinrich-Heine-University, Medical Faculty and University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
6 shared publications - C. Bloechle
Abteilung für Allgemeinchirurgie
5 shared publications
Latest Publications
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S132-S133
338. The role of receptor activator of nuclear factor kappa-B (RANK) – signaling in pancreatic adenocarcinoma
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S132-S133
338. The role of receptor activator of nuclear factor kappa-B (RANK) – signaling in pancreatic adenocarcinoma
- 25 February 2014
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 25 (3) , S49
Percutaneous transhepatic biliary drainage in non-cholestatic patients as treatment for bile leaks after upper abdominal surgery
- 25 February 2014
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 25 (3) , S49
Percutaneous transhepatic biliary drainage in non-cholestatic patients as treatment for bile leaks after upper abdominal surgery
- 24 February 2012
- Vol. 33, 5-9
Surgery in chronic pancreatitis.
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 239-240
Prognostic Impact of Perineural, Blood and Lymph Vessel Invasion for Esophageal Cancer Patients
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 239-240
Prognostic Impact of Perineural, Blood and Lymph Vessel Invasion for Esophageal Cancer Patients
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 193
ALCAM (CD166) Expression is a Positive Predictor for Overall Survival in Colorectal Cancer Patients
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 193
ALCAM (CD166) Expression is a Positive Predictor for Overall Survival in Colorectal Cancer Patients
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 343
The Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule (CEACAM) 1, 5 and 6 as Prognostic Factors in Pancreatic Adenocarcinoma
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 343
The Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule (CEACAM) 1, 5 and 6 as Prognostic Factors in Pancreatic Adenocarcinoma
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 194
Evaluation of TNFAIP3 Gene Polymorphisms as Prognostic Markers in Complete Resected Only Surgically Treated Esophageal Cancer
- 1 February 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 172 (2) , 194
Evaluation of TNFAIP3 Gene Polymorphisms as Prognostic Markers in Complete Resected Only Surgically Treated Esophageal Cancer
- 28 February 2011
- Published by Elsevier in Journal of Surgical Research
- Vol. 165 (2) , 223-224
ALCAM (CD166) Expression As Novel Prognostic Biomarker For Pancreatic Neuroendocrine Tumor Patients
- 28 February 2011
- Published by Elsevier in Journal of Surgical Research
- Vol. 165 (2) , 223-224
ALCAM (CD166) Expression As Novel Prognostic Biomarker For Pancreatic Neuroendocrine Tumor Patients
- 28 February 2011
- Published by Elsevier in Journal of Surgical Research
- Vol. 165 (2) , 176
Prognostic Impact of CXCR4 And CXCR7 Expression In Pancreatic Adenocarcinoma
- 28 February 2011
- Published by Elsevier in Journal of Surgical Research
- Vol. 165 (2) , 176
Prognostic Impact of CXCR4 And CXCR7 Expression In Pancreatic Adenocarcinoma
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 4160
Analysis of four human PlGF isoforms and of VEGFR-1 in esophageal carcinoma.
4160 Background: Placental growth factor (PlGF) and its receptor vascular endothelial growth factor receptor-1 (VEGFR-1) are involved in tumor progression. Humans can express four PlGF isoforms (PlGF1-4), but it is unknown, whether all of them are expressed in cancer. In this retrospective exploratory study, we analyzed expression levels of PlGF1-4 and of VEGFR-1 in primary esophageal tumor tissue and correlated gene expression data with clinical data. We included presence of disseminated tumor cells (DTCs) in the bone marrow in our analysis, which has recently evolved as adverse prognostic factor in different cancers. Methods: Gene expression levels were determined by QRT-PCR in primary tumor samples of 69 patients with esophageal cancer. Subsequently, expression data were correlated with clinical data (pT, pN, pM, DTCs). For analysis of association between expression levels and categorical clinical parameters Wilcoxon's test for independent samples was used. For correlations between quantitative variables, Kendall's tau (τ) was used to measure the degree of dependence. Results: PLGF-1, PLGF-2 and VEGFR-1 were expressed in virtually all analyzed tumor samples. Expression of PLGF-3 and PLGF-4 were limited to 59% and 74% of the analyzed patients, respectively. Expression levels of all PlGF variants were correlated amongst each other (Kendall tau rank>0.55). Expression of PlGF splice variants was not correlated with clinical variables. Interestingly, expression levels of VEGFR-1 predict presence of DTCs in bone marrow (p = 0.002). Patients with DTC in bone marrow had lower expression levels of VEGFR-1 within primary tumor tissue than patients without DTCs (0.004 ± 0.01 vs. 0.07 ± 0.15). In contrast, VEGFR-1 expression level was not correlated with lymphatic or distant macrometastasis, indicating a potential specific role of VEGFR-1 in protecting from dissemination of tumor cells into the bone marrow. Conclusions: All four known isoforms of PLGF are expressed in human esophageal cancer. Furthermore, VEGFR-1 levels are inversely correlated with presence of DTCs in the bone marrow of patients. If validated in prospective studies, VEGFR-1 expression in tumors might serve as novel prognostic biomarker for bone marrow micrometastasis. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 4160
Analysis of four human PlGF isoforms and of VEGFR-1 in esophageal carcinoma.
4160 Background: Placental growth factor (PlGF) and its receptor vascular endothelial growth factor receptor-1 (VEGFR-1) are involved in tumor progression. Humans can express four PlGF isoforms (PlGF1-4), but it is unknown, whether all of them are expressed in cancer. In this retrospective exploratory study, we analyzed expression levels of PlGF1-4 and of VEGFR-1 in primary esophageal tumor tissue and correlated gene expression data with clinical data. We included presence of disseminated tumor cells (DTCs) in the bone marrow in our analysis, which has recently evolved as adverse prognostic factor in different cancers. Methods: Gene expression levels were determined by QRT-PCR in primary tumor samples of 69 patients with esophageal cancer. Subsequently, expression data were correlated with clinical data (pT, pN, pM, DTCs). For analysis of association between expression levels and categorical clinical parameters Wilcoxon's test for independent samples was used. For correlations between quantitative variables, Kendall's tau (τ) was used to measure the degree of dependence. Results: PLGF-1, PLGF-2 and VEGFR-1 were expressed in virtually all analyzed tumor samples. Expression of PLGF-3 and PLGF-4 were limited to 59% and 74% of the analyzed patients, respectively. Expression levels of all PlGF variants were correlated amongst each other (Kendall tau rank>0.55). Expression of PlGF splice variants was not correlated with clinical variables. Interestingly, expression levels of VEGFR-1 predict presence of DTCs in bone marrow (p = 0.002). Patients with DTC in bone marrow had lower expression levels of VEGFR-1 within primary tumor tissue than patients without DTCs (0.004 ± 0.01 vs. 0.07 ± 0.15). In contrast, VEGFR-1 expression level was not correlated with lymphatic or distant macrometastasis, indicating a potential specific role of VEGFR-1 in protecting from dissemination of tumor cells into the bone marrow. Conclusions: All four known isoforms of PLGF are expressed in human esophageal cancer. Furthermore, VEGFR-1 levels are inversely correlated with presence of DTCs in the bone marrow of patients. If validated in prospective studies, VEGFR-1 expression in tumors might serve as novel prognostic biomarker for bone marrow micrometastasis. No significant financial relationships to disclose.